NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL

Launched by THE CHILDREN'S HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE · Jan 2, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a treatment called blinatumomab for children with a type of leukemia known as B-cell acute lymphoblastic leukemia (B-ALL). Specifically, the researchers want to find out if blinatumomab can help children who have already undergone initial treatment (called consolidation therapy) and have either a very small amount of leukemia left (NGS MRD-positive) or none at all (NGS MRD-negative). The main goal is to see if using this medication can improve their chances of long-term survival.

To take part in the study, children need to be between 1 and 17 years old and must be diagnosed with the right type of leukemia based on specific medical tests. Parents or guardians will need to provide consent for their child to participate. The trial is not yet recruiting participants, so while this research is ongoing, interested families may want to keep an eye on it for future opportunities. Those who join the trial will receive treatment and be closely monitored to see how well it works.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Clincial dianogsis of acute lymphoblastic leukemia (B-cell type) by morphology, immunology, cytogenetics, and molecular biology (MICM).
• • Age ≥1 year and \<18 years.
• • Informed consent signed, with the parents or guardians agreeing to a unified treatment protocol.
• Exclusion Criteria:
• • Age \<1 year or ≥18 years.
• • Immunophenotyping suggests mature B-cell leukemia, mixed-lineage leukemia, or T-cell acute lymphoblastic leukemia.
• • Secondary leukemia or second tumor, CML blast phase ALL.
• • Other tumors or immunodeficiency diseases present.